MONTREAL, QUEBEC--(Marketwire - December 04, 2008) - Ambrilia Biopharma Inc. (TSX: AMB) announced today that it has entered into an exclusive license option agreement with ZBx Corporation granting ZBx the worldwide rights to develop, manufacture and commercialize Ambrilia’s PSP94 technology in ZBx’s Zap™ Rapid Test Systems and Assays.
